HVC
Healthcare Value Capital Portfolio holdings
AUM
$38.5M
This Quarter Return
-10.17%
1 Year Return
+22.29%
3 Year Return
+31.09%
5 Year Return
+125.72%
10 Year Return
–
AUM
$23M
AUM Growth
+$23M
(-19%)
Cap. Flow
+$2.94M
Cap. Flow
% of AUM
12.8%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
2
Reduced
–
Closed
–
Top Buys
| 1 |
Gilead Sciences
GILD
|
$1.88M |
| 2 |
ProShares UltraShort NASDAQ Biotechnology
BIS
|
$1.06M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 93.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$140B
| $7.54M | 31.33% | 100,000 +25,000 | +33% | +$1.88M |
|
|
TYME
2
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
| $4.63M | 19.23% | 2,075,000 | – | – |
|
|
NVLN
3
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $3.5M | 14.55% | 1,000,000 | – | – |
|
4
Standard BioTools
LAB
$481M
| $2.4M | 9.96% | 410,500 | – | – |
|
5
GSK
GSK
$79.9B
| $1.95M | 8.12% | 50,000 | – | – |
|
|
6
ProShares UltraShort NASDAQ Biotechnology
BIS
$2.47M
| $1.59M | 6.61% | 75,000 +50,000 | +200% | +$1.06M |
|
|
AMRN
7
Amarin Corp
AMRN
$311M
| $1.36M | 5.63% | 450,000 | – | – |
|
|
SEEL
8
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $41K | 0.17% | 100,000 | – | – |
|
9
MannKind Corp
MNKD
$1.41B
| – | – | 0 | – | – |
|
|
FCSC
10
DELISTED
Fibrocell Science Inc.
FCSC
| – | – | 0 | – | – |
|